Clinical Trials Browser

Phase 2 × Unknown × Anastrozole × Clear all

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Phase 2 Unknown

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

Phase 2 Unknown

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03211572 2017-07-07

OTT 17-01

Phase 2 Unknown

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

Phase 2 Unknown

Breast Neoplasms

NCT02072512 2014-02-26

PROOF

Phase 2 Unknown

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

Phase 2 Unknown

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating